Ayush Gupta’s Post

Exciting Advances in Medical and Pharmaceutical Research! The world of medical and pharmaceutical research is constantly evolving, and recent findings are nothing short of groundbreaking. From innovative treatments to cutting-edge technologies, here are some of the latest developments: 1. CRISPR Gene-Editing Therapy: The FDA approved the first CRISPR/Cas9 gene-editing therapy, targeting sickle cell disease by helping patients produce healthy hemoglobin. 2. Alzheimer’s Drug: Lecanemab, an Alzheimer’s drug, won full FDA approval for its ability to slow cognitive decline by removing amyloid plaques in the brain. 3. RSV Vaccines: New vaccines have been developed to protect against respiratory syncytial virus (RSV), including vaccines for adults and pregnant people. 4. Postpartum Depression Pill: A new pill for postpartum depression has been approved, offering a more convenient alternative to previous treatments. 5. Muscular Dystrophy Gene Therapy: The FDA approved the first gene therapy for children with Duchenne muscular dystrophy, helping the body produce a missing protein essential for muscle function. These advancements are paving the way for a healthier future and showcasing the incredible potential of medical research. Let's continue to support and celebrate these innovations! #MedicalResearch #Pharmaceuticals #Healthcare #Innovation #CRISPR #Alzheimers #RSV #PostpartumDepression #GeneTherapy

Viral Inactivation Market Latest Sales Figure Signals More Opportunities Ahead The Viral Inactivation Market refers to the segment of the biopharmaceutical industry focused on technologies and products used to inactivate or eliminate viruses from biological products. This process is crucial for ensuring the safety of #biopharmaceuticals derived from #biologicalsources, such as #vaccines, #bloodderived products, #recombinantproteins, and #cell and #gene therapy products. Key players in the viral inactivation market include manufacturers of viral inactivation #reagents, #equipment, and #services. These companies develop and provide various technologies for viral inactivation, including heat treatment, solvent/detergent #treatment, #irradiation, and #chemicalmethods. Increasing demand for biopharmaceuticals: As the demand for biopharmaceutical products continues to rise globally, the need for effective viral inactivation methods to ensure product safety becomes more critical. 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅: https://lnkd.in/degm-5bf By Type: Kits and Reagents Services Viral Inactivation Systems and Accessories By Application Blood and Blood Products Cellular and Gene Therapy Products Stem Cell Products Tissue and Tissue Products Vaccines and Therapeutics Companies Profiles in the Report: Danaher Corporation, Merck Group, Parker Hannifin, Sartorius, SGS, Charles River Laboratories International, Clean Cells, Rad Source Technologies, Texcell, Viral Inactivated Plasma Systems, Wuxi Pharmatech (Cayman). #𝒎𝒂𝒓𝒌𝒆𝒕𝒔𝒊𝒛𝒆 #𝒎𝒂𝒓𝒌𝒆𝒕𝒕𝒓𝒆𝒏𝒅𝒔 #𝒎𝒂𝒓𝒌𝒆𝒕𝒇𝒐𝒓𝒆𝒄𝒂𝒔𝒕 #𝒎𝒂𝒓𝒌𝒆𝒕𝒂𝒏𝒂𝒍𝒚𝒔𝒊𝒔 #biopharmaceuticals #biologicalsources, #vaccines, #bloodderived, #recombinantproteins, #cell #gene, #reagents, #equipment, #services, #treatment, #irradiation, #chemicalmethods.

🌶 𝐃𝐚𝐢𝐥𝐲 𝐏𝐡𝐚𝐫𝐦𝐚 𝐃𝐢𝐠𝐞𝐬𝐭 (May 28, 2024) 👇 💊Novartis: Planning regulatory submissions for rare kidney diseases this year. 🧪Johnson & Johnson: Acquired Numab Therapeutics AG Therapeutics’ bispecific antibody NM26 for Phase II studies. 🧬Innovent Biologics: Achieved primary endpoints in Phase 3 trial for moderate to severe plaque psoriasis. 💡RevolKa Ltd.: Signed a master service agreement with Daiichi Sankyo US for protein engineering technology. 🦠Moderna: Reported smaller-than-expected loss for Q1 due to strong Covid vaccine sales. 🔬Merck Group: Acquired gene therapy tools maker for $600 million. 🧫Biogen: Acquired immune drugmaker HI-Bio for $1.15 billion. 🏭Eli Lilly and Company: Invested an additional $5.3 billion in its Indiana plant. 🎯AstraZeneca: Set a sales target of $80 billion by 2030. 🤝Novavax: Experienced a significant turnaround following its partnership with Sanofi. 📉 LOSERS: 🤷♀️AstraZeneca: Failed to show overall survival benefit in non-small cell lung cancer patients. 🚫 Novo Nordisk: FDA Ad-com voted against Icodec once-weekly insulin in Type1 diabetes, 7-4 💰Pfizer: Plans to save $1.5 billion by 2027 through cost-cutting measures. What are your thoughts on these developments? Share your insights below! Don't forget to follow ATACANA GROUP Inc. for daily updates on Pharma winners and losers! #pharmaceuticals #biotech #news #artificialintelligence #competitiveintelligence

Current drug treatments face challenges in patient adherence, limited #personalization and accessibility. In a recent Science Magazine article, authors Jonathan Rivnay, Paul Sheehan, Omid Veiseh envision biohybrid systems to offer transformative solution, using implanted, cell-based "factories" that produce medication within the body on demand, guided by #feedback loops. This approach has shown early success in conditions like blood cancer and #diabetes and could significantly reduce #healthcare costs by avoiding the complex and costly manufacturing processes of #biologic drugs. #Bioelectronics integrated with gene circuits can activate drug synthesis in response to physiological signals, offering a #realtime drug production and #personalized dosage adjustment. Link: https://lnkd.in/erFkcfBB

In this paper, the authors report on their work to establish a CRISPRa based screening platform to identify genes that can enhance productivity. In their work, enhancing expression of a bispecific antibody was investigated. As more complex proteins, such as bispecifics, can be more difficult to express, an approach such as this could be beneficial. #celllineengineering #celllinedevelopment #CRISPR #enhancingproducivity #bispecificantibodies #bsAb #biotherapeutics #biopharmaceuticals https://lnkd.in/ebKJiaJi

The Future of Biopharmaceuticals: A Game Changer in Medicine Biopharmaceuticals are revolutionizing healthcare by offering targeted treatments for conditions previously deemed untreatable. As a pharmacist, I’ve witnessed the transformative potential of biologics in patient care. Here are some key insights: 1. What Are Biopharmaceuticals? These are drugs derived from living organisms, such as monoclonal antibodies, vaccines, and gene therapies, designed to address diseases at their root cause. 2. Why Are They Significant? Biopharmaceuticals provide precision in treatment, often with fewer side effects, and are paving the way for personalized medicine. 3. Challenges in Development Despite their promise, biopharmaceuticals face hurdles like high production costs, complex manufacturing processes, and the need for specialized storage and distribution. 4. Future Outlook Advancements in biotechnology are making biopharmaceuticals more accessible, fostering breakthroughs in areas like cancer immunotherapy and rare genetic diseases. As this field grows, pharmacists play a crucial role in bridging the gap between innovation and patient care.

Join a panel discussion moderated by @Robin Butler with panelists @Rene Gantier, @Rachel Legmann, and @Harlan Knapp to discuss how to apply the lessons learned from mAbs production to advanced therapeutics manufacturing. Register now: https://lnkd.in/gsJcQUTx Free Virtual Event: December 4, 2024 8 AM PST | 11 AM EST | 6 PM CET Bioprocessing Revisited: Applying the Lessons from mAbs Production to Advanced Therapeutics Manufacturing Biotherapeutic manufacturers must move beyond traditional batch and fed-batch processing and look to adopt continuous approaches to increase dose production, reduce costs, and maintain consistent quality. Join a panel of experts from Repligen as we discuss how the lessons learned from monoclonal antibodies (mAbs) production can be applied to advanced therapeutic medicinal products (ATMPs) including gene therapies, cell therapies, nucleic acid-based therapies, oncolytics, vaccines, and exosomes. We will explore the high-impact innovations driving process efficiency in mAbs and vector-based therapeutics production today, from upstream process intensification and downstream chromatography and advanced TFF systems with integrated real-time process analytics, and how these solutions can streamline processes, ensuring higher productivity, scalability, affordability, and accessibility for the therapies of tomorrow. Learning Objectives: * Understand the innovative technologies and strategies that led to boosted mAbs productivity, reduced COGS, and improved quality. * Examine how scalable N perfusion and intensified fed-batch using N-1 perfusion in mAbs and viral vector production can lead to 3X improvements in space-time yield. * Learn how to overcome the unique challenges of advanced therapeutics, ensuring higher productivity, scalability, and cost-effectiveness in ATMP manufacturing. #bioprocessing #ATMP #processintensification

Register today to join the discussion on Applying lessons learned from mAb production and how they can be applied to advanced therapeutics manufacturing today.